Serum ferritin in hepatocellular carcinoma. A comparison with alphafetoprotein

Melia, W M; Bullock, Sarah; Johnson, Philip J.; Williams, Roger

doi:10.1002/1097-0142(19830601)51:11<2112::aid-cncr2820511126>3.0.co;2-6

Cited by 25 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baseline complete blood counts, liver biochemical tests, PT, ␣-fetoprotein (AFP) levels, and ferritin levels were measured. Serum ferritin was measured because it has been described as another useful marker for tumor response, 7 and AFP levels may not be increased in all patients. Other measures, including renal function tests (RFT), antinuclear antibody, thyroid function tests (TFT), and carcinoembryonic antigen levels, also were taken before TAIE treatment.…”

Section: Patient Recruitmentmentioning

confidence: 99%

See 1 more Smart Citation

A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

Yuen¹,

Ooi²,

Hui³

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDSystemic, high–dose interferon‐α treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of transcatheter arterial interferon embolization for the treatment of patients with inoperable HCC.METHODSEighteen patients with inoperable HCC were recruited to receive 3 different doses of interferon‐α‐2b (10 megaunits [MU]/m2, 30 MU/m2, or 50 MU/m2) at intervals of 8–12 weeks. Their tumor response, adverse events, and survival were monitored.RESULTSIn 14 patients with nondiffuse HCC, complete responses and partial responses (> 50% tumor reduction) were observed in 28.6% and 35.7% of patients, respectively. One of four patients with diffuse HCC had a partial response. Thirty‐eight percent of patients had normalization of their α‐fetoprotein level. The median ferritin level at the last follow‐up was reduced significantly (765 pmol/L; range, 457–2720 pmol/L) compared with the baseline level (1980 pmol/L; range, 1100–3300 pmol/L; P = 0.011). The median survival was 15.9 months. Transient fever and rigor were the most common side effects observed. Five patients (27.8%) developed hypothyroidism. No significant liver decompensation was observed.CONCLUSIONSThis pilot study showed that transcatheter arterial interferon embolization was an effective method for the treatment of patients with inoperable HCC without significant hepatic toxicity. Cancer 2003;97:2776–82. © 2003 American Cancer Society.DOI 10.1002/cncr.11400

show abstract

Section: Patient Recruitmentmentioning

confidence: 99%

“…Although ferritin has been used as marker for monitoring response to chemotherapy for patients with HCC, 7 and ferritin also is an acute-phase reactant. Thus, ferritin levels immediately after TAIE treatment may be increased falsely due to systemic inflammatory responses secondary to IFN-␣-2b.…”

Section: Ferritin Responsementioning

confidence: 99%

A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

Yuen¹,

Ooi²,

Hui³

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

“…This may be true for a diversity of cancers like head and neck [1], lung [2], liver [3,4], breast [5], bladder [6] and renal cancer [7] as well as for teratoblastoma [8] and Morbus Hodgkin [9]. The serum ferritin level is also known to be a tumour marker in neuroblastoma patients [10].…”

Section: Introductionmentioning

confidence: 99%

“…Elevated ferritin levels in the serum of cancer patients are commonly used as a tumour marker to get informations about the size, mass and stage of the tumour. This may be true for a diversity of cancers like head and neck [1], lung [2], liver [3,4], breast [5], bladder [6] and renal cancer [7] as well as for teratoblastoma [8] and Morbus Hodgkin [9]. The serum ferritin level is also known to be a tumour marker in neuroblastoma patients [10].…”

Section: Introductionmentioning

confidence: 99%

Mobilization of iron from cellular ferritin by ascorbic acid in neuroblastoma SK‐N‐SH cells: an EPR study

Baader¹,

Bill²,

Trautwein³

et al. 1996

FEBS Letters

View full text Add to dashboard Cite

The mobifization of iron from intracellular ferritin by ascorbic acid has been analysed in sltu by electron paramagentic resonance (EPR) spectroscopy. EPR enables a distinction between ferritins and other Fe3+-binding cellular components. The ordered iron core of ferritin gives rise to a resonance signal which can be observed only at temperatures above 50 K. In the present study we clearly demonstrate that ascorblc acid is capable of mobilizing iron from ferritin in the cellular system by reduction of the ferric ion core in neuroblastoma SK-N-SH cells. This mechanism may open new ways in the therapy of this hardly curable tumor in stage IV, especially in combination with some cytostatic drugs.

show abstract

“…Studies have shown that the restoration of normal serum ferritin levels in cancer patients receiving chemotherapy is associated with treatment response. 22 , 23 Ferritin can reduce ROS damage caused by chemotherapeutic drugs and weaken the killing effect on tumor cells. 2 , 24 Furthermore, increased ferritin expression is closely linked to tumor cell proliferation and can reduce the efficacy of chemotherapeutic drugs.…”

Section: Discussionmentioning

confidence: 99%

Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy

Wang,

Deng,

Liang

et al. 2023

Cancer Biology & Therapy

View full text Add to dashboard Cite

Immunotherapy of lung cancer has achieved promising clinical results. However, it is urgent to develop predictive biomarkers for effective immunotherapy. While ferroptosis plays a critical role in immunotherapy efficacy, ferritin is an important regulatory factor. We, therefore, hypothesize that basal serum ferritin levels before immunotherapy and their corresponding changes during immunotherapy can be useful predictors of immunotherapy response in patients with lung cancer. We measured serum ferritin levels in 107 patients with lung cancer before and during immune checkpoint blockade treatments and studied the correlation between ferritin levels, response rate, and survival. Moreover, the correlation between basal ferritin and PD-L1 expression, tumor stages and pathological types was also analyzed. Patients with lower basal serum ferritin levels before immunotherapy had longer progression-free survival (PFS) (median 7 vs 4 months, P = .023) and higher disease control rate (DCR) (X 2 = 4.837, P = .028), those with downregulated serum ferritin levels during immunotherapy correlated with longer PFS (median 9.5 vs 4 months, P < .001) and higher DCR (X 2 = 6.475, P = .011). However, the “integrated factor”, which was calculated as the combination of lower basal serum ferritin levels before immunotherapy and downregulated serum ferritin levels during immunotherapy, correlated with prolonged PFS ( P < .001). Multivariate analyses revealed that the basal serum ferritin levels before immunotherapy and the corresponding changes during immunotherapy were both strong independent prognostic factors (hazard ratio (HR) = 1.60, P = .041; HR = 2.65, P = .001). These findings suggest that serum ferritin levels can be used as a prognostic biomarker for lung cancer in predicting immunotherapy efficacy.

show abstract

Serum ferritin in hepatocellular carcinoma. A comparison with alphafetoprotein

Cited by 25 publications

References 18 publications

A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

Mobilization of iron from cellular ferritin by ascorbic acid in neuroblastoma SK‐N‐SH cells: an EPR study

Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy

Contact Info

Product

Resources

About